RECEIVED
CENTRAL FAX CENTER
FEB 0 8 2008

AMENDMENTS TO THE CLAIMS

1. (previously presented) A tablet, comprising:

(i) a core containing sumatriptan, and

(ii) a rapid release mantle, free of sumatriptan, wherein the mantle entirely surrounds the core.

2. (original) A tablet according to Claim 1, wherein the weight ratio of mantle:core is equal to or less than 1.8:1.

3. (original) A tablet according to Claim 1, wherein the weight ratio of mantle:core is equal to or less than 1.5:1.

4. (previously presented) A tablet according to any of Claim 1, wherein the core contains from 10-200 mg of sumatriptan.

5. (previously presented) A tablet according to Claim 1, wherein:

(i) the core comprises sumatriptan, a filler, a binder, a disintegrant and a lubricant, and

(ii) the mantle comprises a filler, a binder, a disintegrant and a lubricant.

6. (original) A tablet according to Claim 5, wherein the core and the mantle further comprise adsorbants and/or colorants.

7. (previously presented) A tablet according to Claim 6, wherein the core comprises, by weight:

sumatriptan:	1-40%
filler:	10-90%
binder:	2-60%

disintegrant: 1-60%

lubricant: 0.1-10%

adsorbants: 0-5%

colorants: 0-5%

and the mantle comprises, by weight:

filler: 10-90%

binder: 2-60%

disintegrant: 1-60%

lubricant: 0.1-10%

adsorbants: 0-5%

colorants: 0-5%

8. (previously presented) A tablet according to Claim 6, wherein the core comprises by weight:

sumatriptan: 1-50%

filler: 10-90%

binder: 2-60%

disintegrant: 1-60%

lubricant: 0.1-10%

adsorbants: 0-5%

colorants: 0-5%

and the mantle comprises, by weight:

filler: 10-90%

binder: 2-60%

disintegrant: 1-60%

lubricant: 0.1-10%

adsorbants: 0-5%

colorants: 0-5%

9. (previously presented) A tablet according to Claim 6, wherein the core comprises by weight:

sumatriptan: 5-80%

filler: 10-90%

binder: 2-60%

disintegrant: 1-60%

lubricant: 0.1-10%

adsorbants: 0-5%

colorants: 0-5%

and the mantle comprises, by weight:

filler: 10-90%

binder: 2-60%

disintegrant: 1-60%

lubricant: 0.1-10%

adsorbants: 0-5%

colorants: 0-5%

10. (previously presented) A tablet according to Claim 1, wherein, apart from the sumatriptan in the core, the core and the mantle comprises substantially the same materials.

11. (previously presented) A tablet according to Claim 1, wherein both the core and the mantle dissolve rapidly in the stomach.

12. (original) A tablet according to Claim 11, wherein at least 90% of the tablet is dissolved after 10 minutes.

13. (previously presented) A tablet according to Claim 1, wherein the core and the mantle disintegrate over substantially the same time period.

14. (original) A tablet according to Claim 13, wherein the mantle is at least 95% dissolved and the core is at least 90% dissolved after 10 minutes.

15. (withdrawn) A method of producing a tablet according to Claim 1, comprising the steps of:

(a) forming a core by:

(i) placing a first amount of powder/granule in a press,

(ii) compressing said first amount of powder/granule to obtain a core, and

(b) pressing a second amount of powder/granule around said core, thereby forming a mantle and obtaining the final tablet.

16. (withdrawn) A method of producing a tablet according to Claim 15, comprising the steps of:

(a) forming a core by:

(i) placing a first amount of powder/granule in a press,

(ii) compressing said first amount of powder/granule to obtain a core, and

(b) forming a mantle around the core by:

(i) placing a second amount of powder/granule in a press,

(ii) placing said core onto said second amount of powder/granule,

(iii) placing a third amount of powder/granule on top of the core and the second amount of powder/granule, and

(iv) compressing (iii) so as to obtain the final tablet.

17. (withdrawn) A method according to Claim 15, wherein the compression in Step (a) is carried out at pressure of from 0.5-5 tons.

18. (withdrawn) A method according to Claim 15, wherein the compression in Step (b) is carried out at a pressure from 0.5-10 tons.

19. (withdrawn) A method according to Claim 15, wherein the first amount of powder/granule comprises sumatriptan, a filler, a binder, a disintegrant and a lubricant.

20. (withdrawn) A method according to Claim 19, wherein the first amount of powder/granule further comprises an adsorbant and/or a colorant.

21. (withdrawn) A method according to Claim 15, wherein the first amount of powder/granule comprises, by weight:

sumatriptan:	1-40%
filler:	10-90%
binder:	2-60%
disintegrant:	1-60%
lubricant:	0.1-10%
adsorbants:	0-5%
colorants:	0-5%

22. (withdrawn) A method according to Claim 15, wherein the first amount of powder/granule comprises, by weight:

sumatriptan:	1-50%
filler:	10-90%
binder:	2-60%
disintegrant:	1-60%
lubricant:	0.1-10%
adsorbants:	0-5%
colorants:	0-5%

23. (withdrawn) A method according to Claim 15, wherein the first amount of powder/granule comprises, by weight:

sumatriptan:	5-80%
filler:	10-90%
binder:	2-60%
disintegrant:	1-60%
lubricant:	0.1-10%
adsorbants:	0-5%
colorants:	0-5%

24. (withdrawn) A method according to Claim 15, wherein the second and/or third amounts of powder/granule comprise a filler, a binder, a disintegrant and a lubricant.

25. (withdrawn) A method according to Claim 24, wherein the second and/or third amounts of powder/granule further comprise an adsorbant and/or a colorant.

26. (withdrawn) A method according to Claim 15, wherein the second and/or third amounts of powder/granule comprise, by weight:

filler:	10-90%
binder:	2-60%
disintegrant:	1-60%
lubricant:	0.1-10%
adsorbants:	0-5%
colorants:	0-5%

27. (withdrawn) A method according to Claim 15, wherein Step (a) results in a partially-compressed core, which core is then further compressed in Step (b).